News | June 26, 2021
Shilpa Medicare receives DRDO approval for 2DG manufacturing
2DG has been given emergency approval by the Drug Controller General of India for COVID-19 patients in the country
2DG has been given emergency approval by the Drug Controller General of India for COVID-19 patients in the country
The TWYMEEG approval is supported by numerous preclinical and clinical studies, including the Phase 3 TIMES (Trials of IMeglimin for Efficacy and Safety) program managed jointly by both the companies
Arformoterol Tartrate Inhalation Solution 15 mcg/2 mL is AN-rated generic therapeutic equivalent version of Sunovion Pharmaceuticals Inc.’s Brovana
Celgene will grant Sun Pharma a license to Celgene’s patents required to manufacture and sell certain generic lenalidomide capsules
The company has predominantly built a portfolio into veterinary products
This will enable Mangalam to reduce its reliability on Chinese imports for this product and also help to maintain an uninterrupted supply chain to a great extent
Entered into a manufacturing partnership with Ocugen, Inc. for manufacturing of COVID-19 vaccine COVAXIN for the US and Canadian markets
The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
India is expecting to manufacture 30-35 crore COVID-19 vaccines between July - August 2021
Subscribe To Our Newsletter & Stay Updated
